<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00747357</url>
  </required_header>
  <id_info>
    <org_study_id>BBM-VS-57INDICOR/CRI/07-02/n-c</org_study_id>
    <nct_id>NCT00747357</nct_id>
  </id_info>
  <brief_title>INDICOR The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent</brief_title>
  <acronym>INDICOR</acronym>
  <official_title>The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent to Treat Coronary Artery Disease in a Real World Scenario</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ralf Degenhardt, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Heart Centre Rotenburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The INDICOR study is a controlled, prospective, multicenter, randomized, two arm phase-II&#xD;
      real world study assessing the acute, 6 months, and 12 months and 3 year outcome of&#xD;
      cobalt-chromium stent (Coroflex Blue) deployment followed by Paclitaxel-eluting PTCA-balloon&#xD;
      dilatation (SeQuent Please) and of Paclitaxel-eluting PTCA-balloon dilatation (SeQuent&#xD;
      Please) followed by cobalt-chromium stent (Coroflex Blue) deployment for the treatment of&#xD;
      de-novo and restenotic lesions in native coronary arteries. The study will be conducted in&#xD;
      India.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate the efficacy and safety of cobalt-chromium stent&#xD;
      (Coroflex Blue) deployment followed by Paclitaxel-eluting PTCA-balloon dilatation (SeQuent&#xD;
      Please) and of Paclitaxel-eluting PTCA-balloon dilatation (SeQuent Please) followed by&#xD;
      cobalt-chromium stent (Coroflex Blue) deployment in a real world scenario including up to two&#xD;
      de-novo or restenotic lesions ( no in-stent restenoses) in two different native coronary&#xD;
      arteries (reference diameter: 2.5mm and 4.0mm, length of stenosis 10mm and 25mm) for&#xD;
      procedural success and preservation of vessel patency up to 3 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late lumen loss at 6 months in-segment and in-stent for each treated coronary stenosis</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Coronary Heart Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balloon first</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stent First</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Eluting Balloon SeQuent Please</intervention_name>
    <description>Drug Eluting Balloon is followed by Bare Metal Stent</description>
    <arm_group_label>1</arm_group_label>
    <other_name>SeQuent® Please DEB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug Eluting Balloon SeQuent Please</intervention_name>
    <description>Bare Metal Stent followed by Drug Eluting Balloon</description>
    <arm_group_label>2</arm_group_label>
    <other_name>SeQuent® Please DEB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with stable angina pectoris (CCS class 1-3) or with unstable angina pectoris&#xD;
             (Braunwald class 1-2, A-C) or documented ischemia or with documented silent ischemia&#xD;
&#xD;
          -  Patients eligible for coronary revascularization by means of PCI&#xD;
&#xD;
          -  Patients suitable for coronary revascularization of any sort (balloon angioplasty,&#xD;
             device-assisted balloon-angioplasty or coronary artery bypass grafting)&#xD;
&#xD;
          -  Patients must be older then 18 years of age&#xD;
&#xD;
          -  Women of childbearing potential may not be pregnant nor have the desire to becoming&#xD;
             pregnant during the first year following the study procedure. Hence, patients will be&#xD;
             advised to use an adequate birth control method up to and including 6 months&#xD;
             follow-up.&#xD;
&#xD;
          -  Patients who are mentally and linguistically able to understand the aim of the study&#xD;
             and to show sufficient compliance in following the study protocol&#xD;
&#xD;
          -  Patients must agree to undergo the 6 months angiographic follow-up&#xD;
&#xD;
          -  Patients must agree to undergo the 1 year and 3 year clinical follow-up&#xD;
&#xD;
        Lesion Related (relates to up to 2 stenoses in two different coronary arteries to be&#xD;
        treated per protocol)&#xD;
&#xD;
          -  Reference diameters ranging from 2.5 mm to 4.0 mm and length of stenosis from 10 mm to&#xD;
             ≤ 25 mm&#xD;
&#xD;
          -  Diameter stenosis pre procedure must be either more then 70 % or more then 50 % if&#xD;
             ischemia corresponding to the target lesion is documented either by exercise stress&#xD;
             ECG, stress echocardiography, or scintigraphy&#xD;
&#xD;
          -  Coverage of the target lesion must be intended and possible by a single&#xD;
             Paclitaxel-eluting balloon&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient Related&#xD;
&#xD;
          -  Patients with acute (&lt; 24 h) or recent (≤ 48 hours) myocardial infarction&#xD;
&#xD;
          -  Patients with unstable angina pectoris (Braunwald class 3)&#xD;
&#xD;
          -  Patients with severe congestive heart failure&#xD;
&#xD;
          -  Patients with severe heart failure NYHA IV&#xD;
&#xD;
          -  Patients demonstrating clinical signs of cardiogenic shock at the time of the&#xD;
             procedure (systolic blood pressure of less than 80 mm Hg requiring inotropic support,&#xD;
             IABP and/or fluid challenge).&#xD;
&#xD;
          -  Patients with severe valvular heart disease&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Patients with life expectancy of less than five years or factors making clinical&#xD;
             follow-up difficult&#xD;
&#xD;
          -  Patients with bleeding diathesis in whom anticoagulation or anti-platelet medication&#xD;
             is contraindicated&#xD;
&#xD;
          -  Patients who had a cerebral stroke &lt; 6 months prior to the procedure&#xD;
&#xD;
          -  Patient participates in other clinical trials involving any investigational device or&#xD;
             drug&#xD;
&#xD;
          -  Untreated hyperthyroidism&#xD;
&#xD;
          -  Patient has presence or history of severe renal failure (GFR&lt;30ml/min) and is&#xD;
             therefore not eligible for angiography. Patient's serum creatinine levels must be&#xD;
             documented&#xD;
&#xD;
          -  Post transplantation of any organ or immune suppressive medication&#xD;
&#xD;
          -  Other disease to jeopardize follow-up (e.g., malignancy)&#xD;
&#xD;
          -  Addiction to any drug or to alcohol&#xD;
&#xD;
          -  Patients with any type of surgery during the week preceding the interventional&#xD;
             procedure&#xD;
&#xD;
          -  Patients with percutaneous coronary intervention during the six months prior to&#xD;
             enrollment into this study&#xD;
&#xD;
        Lesion Related&#xD;
&#xD;
          -  Evidence of extensive thrombosis within target vessel before the intervention&#xD;
&#xD;
          -  Side branch &gt; 2 mm in diameter originating from the lesion&#xD;
&#xD;
          -  Percutaneous coronary intervention of venous graft&#xD;
&#xD;
          -  Target segment is occluded of (i.e., acute or chronic)&#xD;
&#xD;
          -  In-stent restenosis (restenoses in non-stented segments are permitted)&#xD;
&#xD;
          -  Ostial lesion within 2 mm of vessel origin&#xD;
&#xD;
          -  Patients with another coronary stent implanted previously into the target vessel&#xD;
             proximal to the target lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Upendra kAUL, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fortis Flt.Lt.Rajan Dhall Hospital, New Delhi, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Upendra Kaul</name>
      <address>
        <city>New Delhi</city>
        <zip>110025</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>September 4, 2008</study_first_submitted>
  <study_first_submitted_qc>September 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2008</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Heart Centre Rotenburg</investigator_affiliation>
    <investigator_full_name>Ralf Degenhardt, PhD</investigator_full_name>
    <investigator_title>Data Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

